Background Selective BRAF inhibitors, vemurafenib and dabrafenib, and the MEK inhibitor,
trametinib, have been approved for treatment of metastatic melanomas with a BRAF p …

Tumors are complex masses composed of malignant and non-malignant cells. Variation in
tumor purity (proportion of cancer cells in a sample) can both confound integrative analysis …

Cytological evaluation of pancreatic or biliary duct brushings is a specific, but insensitive,
test for malignancy. We compared adjunctive molecular testing with next-generation …

Precision medicine, a concept that has recently emerged and has been widely discussed,
emphasizes tailoring medical care to individuals largely based on information acquired from …

The discovery and clinical application of molecular biomarkers in solid tumors, increasingly
relies on nucleic acid extraction from FFPE tissue sections and subsequent molecular …

Activating mutations in downstream genes of the epidermal growth factor receptor (EGFR)
pathway may cause anti-EGFR resistance in patients with colorectal cancers. We present …

Objectives: To assess the performance of a next-generation sequencing (NGS) platform for
the clinical detection of BRAF mutations. Methods: In this retrospective quality assessment of …

Cytology samples are increasingly used for comprehensive molecular testing. Although fine-
needle aspirates are adequate substrates for high-throughput sequencing, the suitability of …

Lung cancer is the leading cause of cancer death in the United States. Gene alterations are
significant in lung tumorigenesis, with certain genes (Kristen rat sarcoma viral oncogene …

Tumour content plays a pivotal role in directing the bioinformatic analysis of molecular
profiles such as copy number variation (CNV). In clinical application, tumour purity …